The Radiofrequency Ablation Devices Market Is Witnessing Strong Growth As Medtronic Launched Accurian(TM) RF Ablation Platform
The growing use of ablation devices for pain management is driving the growth of the global radiofrequency ablation devices market. So, the increasing prevalence of arthritis around the globe is uplifting the growth of the market. According to the Centers for Disease Control and Prevention (CDC)’s May 2019 report, an estimated 54.4 million US adults have been diagnosed with arthritis, which accounted for around 1 in 4 people in the U.S. Moreover, the growing geriatric population is also projected to augment the growth of the radiofrequency ablation devices market. According to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034. Furthermore, the growing demand for minimally invasive procedures is further projected to foster the growth of the market over the forecast period.
North America is expected to exhibit significant growth over the forecast period and this is attributed to the continuous innovation by ley players in the field of radiofrequency ablation devices. For instance, in November 2020, Abbott announced the launch of the IonicRF™ Generator – a new device recently cleared by the U.S. Food and Drug Administration to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system. The IonicRF Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain.
Key Developments:
1 In May 2019, Boston Scientific Corporation entered into a definitive agreement to acquire Vertiflex, Inc., a developer of minimally-invasive devices for pain management.
2 In February 2019, Medtronic plc announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Accurian(TM) RF ablation platform, which conducts radio frequency (RF) ablation of nerve tissues.

Comments
Post a Comment